CD Genomics proprietary GenSeqTM genetic panel is based on a technology that assesses a complex but specific set of sites on the human genome -- single nucleotide polymorphisms (SNPs) – that determine which individual is more likely to develop lung cancer.More information, please visit the website: http://www.cd-genomics.com/Lung-Cancer-Susceptibility-of-Smokers.html